Tag: BB-031
Basking doses first patients in phase-one study of stroke drug reversal...
Basking Biosciences has announced that the first participants have been dosed in a phase-one clinical study of BB-025—a rapid-acting reversal agent designed to specifically...
Basking Biosciences doses first patients in part B of RAISE trial...
Basking Biosciences has announced the first patients have been dosed in part B of its Phase 2 RAISE trial of BB-031, an investigational ribonucleic...
Reversible thrombolytic could alleviate US “tribalism” around tPA and help redefine...
Following Basking Biosciences’ recent announcement that the first acute ischaemic stroke patients have received its novel thrombolytic therapy as part of the Phase 2...
Basking Biosciences closes US$55 million financing to further reversible stroke thrombolytic
Basking Biosciences has announced the close of US$55 million in financing, which will be used to accelerate clinical development of its novel thrombolytic therapy...
